Pharma BD Deal Intelligence
Shire plc / Lumena Pharmaceuticals, Inc.
2014 · Acquisition/Merger · $260M · Complete
Announcement Sentiment
67
Positive
Shire acquired privately held Lumena Pharmaceuticals for $260M upfront plus near-term contingent milestones, adding two oral ASBT inhibitors—LUM001 in Phase 2 across four orphan cholestatic indications and LUM002 ready to enter Phase 2 in NASH. Strengthened Shire's GI/hepatic rare-disease franchise.
Did it work? Outcome assessment Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Stalled
Assessment window: 10yr post-close.
Key facts
Announced Jun 03, 2014 Closed Jun 11, 2014 Deal value $260M Deal type Acquisition/Merger Therapeutic area Cholestatic liver disease, primary biliary cholangitis, NASH Indications Cholestatic liver disease, primary biliary cholangitis, NASH Key assets LUM001 (maralixibat) and LUM002 (volixibat) Mechanism Apical sodium-dependent bile acid transporter (ASBT) inhibition
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About